PF-07257876
PF-07257876 is a CD47/PD‑L1 bispecific antibody that preferentially targets tumor cells through high PD-L1 affinity and weak CD47 affinity. PF‑07257876 simultaneously blocks the CD47‑SIRPα innate immune checkpoint and the PD‑L1/PD‑1 adaptive immune checkpoint, activates dendritic cells and macrophages, enhances CD8+ T cell infiltration within the tumor microenvironment, and synergistically mobilizes innate and adaptive immunity to exert antitumor effects. PF-07257876 can be used in research on CD47/PD‑L1-related cancers, such as ovarian cancer and non-small cell lung cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Species Reactivity
Human
In Vitro
PF‑07257876 can dually inhibit the CD47‑SIRPα and PD‑L1‑PD‑1 immune checkpoint axes, activate dendritic cells and macrophages, enhance CD8+ T cell infiltration in the tumor microenvironment, and generate an innate‑adaptive combined antitumor immune response[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Target
CD47 & PDL1
Conjugated
Unconjugated
Application
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[PF- 07257876]
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PF-07257876 Related Classifications
HY-P992553 Related Classifications
Powered by Bioz